Athanasopoulou Foteini, Manolakakis Michail, Vernia Santiago, Kamaly Nazila
Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London, W12 0BZ, UK.
MRC London Institute of Medical Sciences, Du Cane Road, London, W12 0NN, UK.
Nanomedicine (Lond). 2023 Jan;18(1):67-84. doi: 10.2217/nnm-2022-0261. Epub 2023 Mar 10.
Nanomedicines are revolutionizing healthcare as recently demonstrated by the Pfizer/BioNTech and Moderna COVID-2019 vaccines, with billions of doses administered worldwide in a safe manner. Nonalcoholic fatty liver disease is the most common noncommunicable chronic liver disease, posing a major growing challenge to global public health. However, due to unmet diagnostic and therapeutic needs, there is great interest in the development of novel translational approaches. Nanoparticle-based approaches offer novel opportunities for efficient and specific drug delivery to liver cells, as a step toward precision medicines. In this review, the authors highlight recent advances in nanomedicines for the generation of novel diagnostic and therapeutic tools for nonalcoholic fatty liver disease and related liver diseases.
纳米药物正在彻底改变医疗保健行业，辉瑞/ BioNTech和莫德纳的2019冠状病毒病疫苗最近就证明了这一点，全球已安全接种了数十亿剂。非酒精性脂肪性肝病是最常见的非传染性慢性肝病，对全球公共卫生构成了日益严峻的重大挑战。然而，由于诊断和治疗需求尚未得到满足，人们对开发新的转化方法有着浓厚的兴趣。基于纳米颗粒的方法为向肝细胞高效、特异性地递送药物提供了新机会，这是迈向精准药物的一步。在这篇综述中，作者强调了纳米药物在开发用于非酒精性脂肪性肝病及相关肝病的新型诊断和治疗工具方面的最新进展。
